| 1 |
NCT02517320 |
Completed |
Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy |
|
- Drug: MT-3995 Low
- Drug: MT-3995 Middle
- Drug: MT-3995 High
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Mitsubishi Tanabe Pharma Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change form baseline in UACR
- Change in UACR classification
- Change in renal function
- (and 2 more...)
|
293 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT02517320 |
MT-3995-J05 |
|
July 2015 |
November 2016 |
January 2017 |
August 7, 2015 |
March 3, 2017 |
|
- Investigational site
Hokkaido, Japan
|
|
| 2 |
NCT03824379 |
Not yet recruiting
New |
Magnesium Supplementation in Diabetic Nephropathy |
|
- Dietary Supplement: Magnesium citrate
- Drug: Antidiabetic
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change of Human Serum Osteocalcin level
- Serum Insulin
- The homeostasis model assessment-estimated insulin resistance (HOMA-IR)
- (and 9 more...)
|
60 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03824379 |
PHCL932 |
|
March 1, 2019 |
November 1, 2019 |
November 1, 2019 |
January 31, 2019 |
January 31, 2019 |
|
|
|
| 3 |
NCT02205372 |
Completed |
Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy |
|
- Drug: MT-3995
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Mitsubishi Tanabe Pharma Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Frequency and nature of treatment-emergent adverse events and serious adverse events.
- Plasma concentrations of MT-3995
- Plasma concentrations of major metabolite of MT-3995
- (and 2 more...)
|
31 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT02205372 |
MT-3995-J04 |
|
July 2014 |
August 2015 |
August 2015 |
July 31, 2014 |
September 16, 2015 |
|
- Touei Hospital
Sapporo, Hokkaido, Japan
|
|
| 4 |
NCT02204280 |
Completed |
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy |
|
|
Observational
|
|
- Hebei Medical University Third Hospital
- Sixth Affiliated Hospital, Sun Yat-sen University
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- The urine UbA52 levels in 30 patients with type 2 diabetic mellitus,30 patients with diabetic nephropathy，30 patients with proteinuria due to nondiabetic renal disease and 30 healthy persons
|
120 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02204280 |
HebeiMUTH |
|
August 2014 |
July 2015 |
July 2015 |
July 30, 2014 |
July 21, 2015 |
|
|
|
| 5 |
NCT01889277 |
Completed |
Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy |
|
- Drug: MT-3995-Low
- Drug: MT-3995-High
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Mitsubishi Tanabe Pharma Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Frequency and nature of treatment-emergent adverse events and serious adverse events.
- Plasma concentrations of MT-3995 and its major metabolite
- Change from baseline in Urine albumin-to-creatinine ratio (UACR) and blood pressure
|
51 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT01889277 |
MT-3995-J03 |
|
July 2013 |
January 2015 |
January 2015 |
June 28, 2013 |
January 27, 2015 |
|
- Koukan Hospital
Kawasaki, Kanagawa Pref., Japan
|
|
| 6 |
NCT03436693 |
Recruiting |
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy |
|
- Drug: Canagliflozin
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Mitsubishi Tanabe Pharma Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The proportion of subjects with a decline in estimated glomerular filtration rate (eGFR) from baseline at Week 104
- Change from baseline in eGFR at each assessment time point
- Time to the first occurrence of an event in the composite endpoint: end-stage renal disease (ESRD), doubling of serum creatinine, renal death, or cardiovascular (CV) death
- Change from baseline in urine albumin-to-creatinine ratio (UACR) at each assessment time point
|
300 |
All |
30 Years and older (Adult, Older Adult) |
NCT03436693 |
TA-7284-14 |
|
February 15, 2018 |
September 2021 |
September 2021 |
February 16, 2018 |
April 5, 2018 |
|
- Research site
Aichi, Japan - Research site
Chiba, Japan - Research site
Fukuoka, Japan - (and 23 more...)
|
|
| 7 |
NCT02704494 |
Completed |
Resveratrol's Effects in Diabetic Nephropathy |
|
- Drug: Resveratrol
- Drug: Placebo
- Drug: Losartan
|
Interventional
|
Early Phase 1 |
- Shiraz University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Urine albumin level
- Serum creatinin
- Fasting blood sugar (FBS)
- (and 4 more...)
|
60 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02704494 |
93-01-49-9028 |
ReDNeph |
March 2016 |
February 2017 |
February 2017 |
March 10, 2016 |
October 5, 2017 |
|
- Shahid Motahhari Clinic, Shiraz University of Medical Sciences
Shiraz, Fars, Iran, Islamic Republic of
|
|
| 8 |
NCT03407989 |
Recruiting |
SWIDINEP a Swiss Diabetic Nephropathy Cohort |
|
|
Observational
|
|
- Centre Hospitalier Universitaire Vaudois
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- estimated GFR decline ml/min/y
- 24 hour blood pressure measurements (mmHg) and eGFR decline (ml/min/y)
- Vascular markers (Pulse wave velocity (m/s); Carotid and radial augmentation indexes (%); intima media thickness (mm)) and eGFR decline (ml/min/y)
- (and 6 more...)
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03407989 |
CER 43/12 |
SWIDINEP |
January 1, 2014 |
January 1, 2022 |
January 1, 2022 |
January 23, 2018 |
January 24, 2018 |
|
- Centre Hospitalier Universitaire Vaudois
Lausanne, Vaud, Switzerland
|
|
| 9 |
NCT03147677 |
Recruiting |
Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan |
- Type 2 Diabetic Nephropathy
|
- Drug: Alfacalcidol
- Drug: Irbesartan
|
Interventional
|
Phase 4 |
- The Third Xiangya Hospital of Central South University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in 24h urinary albumin excretion rate (UAER) by comparing visits at week 20 with the baseline
- Changes in 24h urinary protein quantity by comparing visits at week 20 with the baseline
- Changes in estimated glomerular filtration rate (eGFR) by comparing visits at week 20 with the baseline
- (and 3 more...)
|
216 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03147677 |
320.6750.16025 |
|
July 2016 |
July 2018 |
December 2018 |
May 10, 2017 |
October 25, 2017 |
|
- The Third Xiangya Hospital of Central South University
Changsha, Hunan, China - Hunan Chenzhou NO.1 People's Hospital
Chenzhou, Hunan, China - Hunan Yiyang Central Hospital
Yiyang, Hunan, China
|
|
| 10 |
NCT01756703 |
Completed |
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria |
|
- Drug: MT-3995 Low
- Drug: MT-3995 High
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Mitsubishi Tanabe Pharma Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage change from baseline in Urine albumin-to-creatinine ratio (UACR) within group.
- Frequency and nature of treatment-emergent adverse events and serious adverse events.
- Percentage change from baseline in UACR compared to placebo
- (and 2 more...)
|
67 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01756703 |
MT-3995-E06 |
|
November 2012 |
August 2014 |
August 2014 |
December 27, 2012 |
February 9, 2015 |
|
- Investigational site
Blagoevgrad, Bulgaria - Investigational site
Burgas, Bulgaria - Investigational site
Byala, Bulgaria - (and 40 more...)
|
|
| 11 |
NCT01756716 |
Completed |
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR |
|
- Drug: MT-3995 Low
- Drug: MT-3995 High
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Mitsubishi Tanabe Pharma Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage change from baseline in Urine albumin-to-creatinine ratio (UACR) within group.
- Frequency and nature of treatment-emergent adverse events and serious adverse events.
- Percentage change from baseline in UACR compared to placebo
- (and 2 more...)
|
49 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01756716 |
MT-3995-E07 |
|
December 2012 |
September 2014 |
September 2014 |
December 27, 2012 |
February 9, 2015 |
|
- Investigational site
Blagoevgrad, Bulgaria - Investigational site
Pazardzhik, Bulgaria - Investigational site
Pleven, Bulgaria - (and 47 more...)
|
|
| 12 |
NCT03658317 |
Not yet recruiting |
Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy |
|
- Diagnostic Test: renal arterial resistive index
- Diagnostic Test: uric acid level
- Diagnostic Test: serum urea and creatinine
- (and 5 more...)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- renal resistive index
- stage of diabetic nephropathy
|
150 |
All |
Child, Adult, Older Adult |
NCT03658317 |
RI in diabetic nephropathy |
|
September 2018 |
March 2019 |
September 2019 |
September 5, 2018 |
September 14, 2018 |
|
|
|
| 13 |
NCT03804879 |
Recruiting |
Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy |
|
- Drug: LMB763
- Other: Placebo
|
Interventional
|
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- effect of LMB763 to placebo on albuminuria in patients with diabetic nephropathy already receiving treatment with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
- Adverse event profile and safety endpoints of LMB763
- effect of LMB763 on renal filtration function utilizing Estimated glomerular filtration rate
- (and 6 more...)
|
100 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03804879 |
CLMB763X2202 |
|
February 5, 2019 |
May 28, 2021 |
May 28, 2021 |
January 15, 2019 |
February 15, 2019 |
|
- Novartis Investigative Site
Miami Lakes, Florida, United States - Novartis Investigative Site
Norman, Oklahoma, United States
|
|
| 14 |
NCT03288571 |
Not yet recruiting |
Use of Wharton Jelly in Diabetic Nephropathy |
|
- Biological: Wharton Jelly Mesenchymal stem cells
|
Interventional
|
Phase 1
Phase 2 |
- Sophia Al-Adwan
- Jordan University of Science and Technology
- An-Najah National University
- University of Jordan
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Evaluation of the preliminary efficacy of the injection on kidney's Estimated Glomerular filtration rate
- Evaluation of the preliminary efficacy of the injection on kidney's protein to creatinine ratio
|
20 |
All |
35 Years to 70 Years (Adult, Older Adult) |
NCT03288571 |
DNJUCTC |
|
November 2019 |
December 2019 |
January 2020 |
September 20, 2017 |
June 6, 2018 |
|
|
|
| 15 |
NCT02442921 |
Recruiting |
Colchicine for Diabetic Nephropathy Trial |
|
- Drug: Colchicine
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Sheba Medical Center
- D-Cure, Israel
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change of urinary protein excretion ( mg/24hrs) from baseline to 18 months.
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT02442921 |
SHEBA-2015-1560-SK-CTIL |
CDNT |
February 22, 2016 |
April 30, 2019 |
April 30, 2019 |
May 13, 2015 |
May 9, 2017 |
|
- Sheba Medical Center
Ramat Gan, Israel
|
|
| 16 |
NCT03174821 |
Completed |
Effect Insulin Pump Therapy to Patients With Diabetic Nephropathy |
- Insulin Pump Therapy in Treating Diabetic Nephropathy
|
|
Interventional
|
Not Applicable |
- Chinese PLA General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The change of 8-hydroxy-deoxyguanosine (8-OHdG)
- The change of 3-nitrotyrosine (3-NT)
- The change of glutathione (GSH)
- The change of superoxide dismutase (SOD)
|
160 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03174821 |
IPT-OX-10 |
|
October 20, 2010 |
May 16, 2014 |
May 16, 2014 |
June 5, 2017 |
June 5, 2017 |
|
|
|
| 17 |
NCT00317954 |
Completed |
Spironolactone in Diabetic Nephropathy |
|
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Changes in albuminuria
- Changes in blood pressure
- Changes in glomerular filtration rate
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT00317954 |
2612-2233 |
|
September 2003 |
|
July 2005 |
April 25, 2006 |
April 25, 2006 |
|
- Steno Diabetes Center
Gentofte, Denmark
|
|
| 18 |
NCT00708981 |
Completed |
Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) |
|
- Other: Multifactorial Intervention
|
Interventional
|
Phase 4 |
- John H. Stroger Hospital
- Sanofi
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Delay in development in end-stage renal failure in subjects with Advanced Diabetic Nephropathy (CKD stages 3 and 4)
|
120 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00708981 |
Metabolism IST
IRB# 06-177 |
|
May 2007 |
October 2013 |
December 2013 |
July 3, 2008 |
October 2, 2014 |
|
- John H. Stroger Jr. Hospital of Cook County
Chicago, Illinois, United States
|
|
| 19 |
NCT02690883 |
Unknown † |
Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy |
|
- Drug: Exenatide
- Drug: Lispro
|
Interventional
|
Phase 4 |
- Nanfang Hospital of Southern Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- the percentage change of 24h-UAER(urinary albumin excretion rates) from baseline at Week 24
|
90 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02690883 |
ESR-14-10425 |
|
March 2016 |
March 2017 |
October 2017 |
February 24, 2016 |
February 24, 2016 |
|
|
|
| 20 |
NCT02768948 |
Recruiting |
Telmisartan Promotes the Differentiation of Monocytes Into Macrophages M2 in Diabetic Nephropathy? |
|
- Drug: telmisartan during 6 months
- Drug: Losartan during 6 months
- Procedure: blood sample
|
Interventional
|
Not Applicable |
- Centre Hospitalier Universitaire de Nice
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- number of differentiation marker
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02768948 |
16-AOI-09 |
|
May 5, 2017 |
July 2019 |
July 2019 |
May 11, 2016 |
November 21, 2018 |
|
|
|
| 21 |
NCT00782847 |
Completed |
Evaluation Study for the Programme DiaNe for People With Diabetic Nephropathy |
|
- Behavioral: DiaNe consultation and support program
|
Interventional
|
Phase 3 |
- DiaNe HCM GmbH
- Roche Pharma Deutschland GmbH, Grenzach-Wyhlen, Germany
- Institute for Medical Outcom Research GmbH, Loerrach, Germany
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- deterioration of kidney function in diabetic nephropathy
- HbA1c
|
125 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00782847 |
DiaNe-Studie |
DiaNe |
July 2004 |
January 2007 |
January 2007 |
October 31, 2008 |
October 31, 2008 |
|
- Diabetes- und Nierenzentrum Dormagen
Dormagen, NRW, Germany
|
|
| 22 |
NCT01005121 |
Unknown † |
Colchicine for Diabetic Nephropathy |
|
|
Interventional
|
Phase 2 |
- Prof.Avi Livneh
- Sheba Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 24 hr urine protein collection
|
12 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT01005121 |
SHEBA-09-7369-AL-CTIL |
|
December 2009 |
December 2014 |
December 2015 |
October 30, 2009 |
January 4, 2013 |
|
- Sheba medical center, Tel hashomer
Ramat gan, Israel
|
|
| 23 |
NCT01779089 |
Unknown † |
Minocycline and Proteinuria in Diabetic Nephropathy |
|
- Drug: Minocycline 100 mg po bid for 6 months
- Drug: placebo
|
Interventional
|
Not Applicable |
- Los Angeles Biomedical Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in 24 hour urine protein/creatinine ratio (average of 2 values) baseline compared to 6-months in placebo vs minocycline
- Change in average MACR in 24 hour urine, daytime and overnight collections (baseline vs 6 mos)
- Change in average 24 hour urine protein/creatinine in daytime vs overnight collections, baseline vs 6 mos
- Change in urine and blood biomarkers in minocycline vs placebo treated patients at baseline vs 6 mos
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT01779089 |
013400 |
|
February 2009 |
March 2016 |
March 2016 |
January 30, 2013 |
May 21, 2015 |
|
- Los Angeles Biomedical Reaearch Institute at Harbor-UCLA Medical Center
Torrance, California, United States
|
|
| 24 |
NCT01003236 |
Completed |
Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy |
|
- Drug: placebo
- Drug: Milk Thistle extract
|
Interventional
|
Phase 2 |
- Shiraz University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in urinary albumin-creatinine ratio
- Change from baseline in urinary TNF-α
- Change from baseline in urinary TGF-β
- (and 9 more...)
|
60 |
All |
30 Years to 70 Years (Adult, Older Adult) |
NCT01003236 |
4774 |
|
October 2010 |
October 2011 |
November 2011 |
October 28, 2009 |
June 25, 2012 |
|
- Motahari Clinic
Shiraz, Fars, Iran, Islamic Republic of
|
|
| 25 |
NCT02488252 |
Recruiting |
Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy |
|
- Drug: Semi-individualised Chinese Medicine treatment
- Drug: Routine medical care (active comparator)
|
Interventional
|
Phase 2
Phase 3 |
- The University of Hong Kong
- School of Chinese Medicine, The University of Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in estimated GFR
- Change in spot urine albumin-to-creatinine ratio
- Change in fasting blood glucose (FBG)
- (and 11 more...)
|
148 |
All |
35 Years to 80 Years (Adult, Older Adult) |
NCT02488252 |
DN-CM-1 |
SCHEMATIC |
July 2015 |
June 2019 |
December 2019 |
July 2, 2015 |
May 17, 2018 |
|
- Queen Mary Hospital
Hong Kong, Hong Kong
|
|
| 26 |
NCT01858532 |
Terminated |
Study Of Diabetic Nephropathy With Atrasentan |
|
- Drug: Atrasentan
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to the first occurrence of a component of the composite renal endpoint.
- Time to first occurrence of a component of composite renal endpoint: confirmed doubling of serum creatinine or the onset of end stage renal disease for all randomized subjects (pooled).
- Time to a 50% estimated glomerular filtration rate reduction.
- (and 2 more...)
|
5112 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01858532 |
M11-352
2012-005848-21 |
SONAR |
May 17, 2013 |
March 29, 2018 |
March 29, 2018 |
May 21, 2013 |
April 26, 2018 |
|
- Nephrology Associates P.C.
Birmingham, Alabama, United States - University of Alabama
Birmingham, Alabama, United States - Nephrology Consultants, LLC
Huntsville, Alabama, United States - (and 793 more...)
|
|
| 27 |
NCT02410499 |
Withdrawn |
Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria |
|
- Drug: MLN1202 Placebo
- Drug: MLN1202
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) at Day 85
- Change from Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) Over Time
- Change from Baseline in Urinary Protein:Creatinine Ratio (UPCR) Over Time
|
0 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT02410499 |
MLN1202-2005
2014-005142-21
U1111-1168-1426 |
|
May 20, 2015 |
November 17, 2015 |
November 17, 2015 |
April 7, 2015 |
September 25, 2017 |
|
|
|
| 28 |
NCT00967629 |
Completed |
Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy |
|
- Drug: Sevelamer Carbonate
- Drug: Calcium Carbonate
|
Interventional
|
Phase 1 |
- Icahn School of Medicine at Mount Sinai
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- serum AGE levels
- inflammatory markers
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT00967629 |
GCO 08-0976 |
|
June 2009 |
February 2010 |
February 2010 |
August 28, 2009 |
November 18, 2011 |
|
- Mount Sinai School of Medicine
New York, New York, United States
|
|
| 29 |
NCT00130312 |
Terminated |
Effect of Sulodexide in Overt Diabetic Nephropathy |
|
|
Interventional
|
Phase 4 |
- Keryx Biopharmaceuticals
- Collaborative Study Group (CSG)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to doubling of the serum creatinine or end stage kidney disease (ESRD)
- Safety and tolerance of sulodexide therapy long-term
- Change in urinary protein/albumin excretion
|
1248 |
All |
18 Years and older (Adult, Older Adult) |
NCT00130312 |
KRX-101-401 |
|
August 2005 |
March 2008 |
March 2008 |
August 15, 2005 |
May 5, 2015 |
|
- The Collaborative Study Group, Clinical Coordinating Center for U.S. and Canadian clinics, Rush University Medical Center
Chicago, Illinois, United States - The Collaborative Study Group, Clinical Coordinating Center for the Pacific Region, Monash Medical Center
Clayton / Melbourne, Victoria, Australia - The Collaborative Study Group, Clinical Coordinating Center for European Clinics, University of Groningen
Groningen, Netherlands
|
|
| 30 |
NCT01774981 |
Completed
Has Results |
Study of LY3016859 in Participants With Diabetic Nephropathy |
|
- Drug: Placebo
- Drug: LY3016859
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Part B:Change From Baseline in Proteinuria
- Part A and Part B: Number of Participants With One or More Treatment Emergent Adverse Events (AEs) or Any Serious AEs
- Part B: Change From Baseline in Proteinuria Over Time
- Part B: Change From Baseline in Albuminuria Over Time
|
60 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01774981 |
14353
I5V-MC-TGAB
2012-004496-40 |
|
March 2013 |
August 2015 |
August 2015 |
January 24, 2013 |
October 6, 2017 |
August 15, 2017 |
- Innovative Research of West Florida
Clearwater, Florida, United States - Creighton University Medical Center
Omaha, Nebraska, United States - Northeast Clinical Research Center
Bethlehem, Pennsylvania, United States - (and 4 more...)
|
|
| 31 |
NCT01796418 |
Unknown † |
Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy |
|
|
Interventional
|
Not Applicable |
- Seoul National University Hospital
- Astellas Pharma Korea, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Brachial ankle pulse wave velocity (PWV)
- Ankle brachial indices (ABI)
- Urine albumin creatinine ratio (UACR)
- (and 3 more...)
|
102 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT01796418 |
BESTinDN-001 |
|
March 2013 |
August 2014 |
|
February 21, 2013 |
December 16, 2013 |
|
- Hallym University Sacred Heart Hospital
Anyang, Korea, Republic of - Seoul National University Bundang Hospital
Seongnam, Korea, Republic of - Kangnam Sacred Heart Hospital
Seoul, Korea, Republic of - (and 2 more...)
|
|
| 32 |
NCT01935167 |
Completed |
To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy |
|
- Drug: DW1029M 600mg
- Drug: DW1029M 1200mg
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Dong Wha Pharmaceutical Co. Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- log ACR
- Log UAE
- eGFR
- (and 2 more...)
|
158 |
All |
30 Years and older (Adult, Older Adult) |
NCT01935167 |
DW1029M |
|
October 2013 |
August 2014 |
February 2015 |
September 4, 2013 |
February 17, 2017 |
|
- DongWha Pharm
Seoul, Korea, Republic of
|
|
| 33 |
NCT01068041 |
Completed |
Effects of PH3 in Diabetic Nephropathy |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Urinary Albumin/Creatinine Ratio (UACR)
- Urine Albumin Serum Creatinine and the estimated GFR (glomerular filtration rate) HbA1c
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01068041 |
PH-CP016 |
PH3 |
August 2010 |
July 2014 |
September 2015 |
February 12, 2010 |
November 4, 2015 |
|
- Taichung Veterans General Hospital
Taichung, Taiwan - Tri-Service General Hospital
Taipei, Taiwan - Taipei Veterans General Hospital
Taipei, Taiwan
|
|
| 34 |
NCT00870402 |
Unknown † |
Aldosterone in Diabetic Nephropathy |
|
- Drug: Spironolactone
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Universidad Los Andes
- Universidad de los Andes, Chile
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Reduction of albuminuria
- Reduction of diastolic disfunction
|
160 |
All |
30 Years to 70 Years (Adult, Older Adult) |
NCT00870402 |
SA08I20032 |
ALDODN |
March 2009 |
December 2009 |
March 2010 |
March 27, 2009 |
March 27, 2009 |
|
- University of Los Andes
Santiago, Chile
|
|
| 35 |
NCT01768611 |
Completed |
SLC2A1 Variants and Diabetic Nephropathy |
|
|
Observational
|
|
- University of Sao Paulo General Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
|
449 |
All |
11 Years and older (Child, Adult, Older Adult) |
NCT01768611 |
FMUSP-LIM25-001 |
|
October 2004 |
October 2012 |
October 2012 |
January 15, 2013 |
January 16, 2013 |
|
- Faculdade de Medicina da USP
São Paulo, SP, Brazil
|
|
| 36 |
NCT01273675 |
Unknown † |
An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy |
|
|
Observational
|
|
- National Taiwan University Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
100 |
All |
30 Years to 75 Years (Adult, Older Adult) |
NCT01273675 |
201008056R |
|
September 2010 |
|
|
January 10, 2011 |
January 10, 2011 |
|
|
|
| 37 |
NCT00320060 |
Completed |
Effect of Pyridorin in Patients With Diabetic Nephropathy |
|
- Drug: Pyridorin (pyridoxamine dihydrochloride)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
128 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00320060 |
PYR-206 |
|
October 2001 |
|
January 2003 |
April 27, 2006 |
April 27, 2006 |
|
|
|
| 38 |
NCT00320021 |
Completed |
Effect of Pyridorin in Patients With Diabetic Nephropathy |
|
- Drug: Pyridorin (pyridoxamine dihydrochloride)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Change in Serum Creatinine from baseline to week 26
|
80 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00320021 |
PYR-205/207
PYR-205
PYR-207 |
|
July 2002 |
|
September 2003 |
April 27, 2006 |
April 27, 2006 |
|
|
|
| 39 |
NCT00565318 |
Completed |
Benfotiamine in Diabetic Nephropathy |
|
- Drug: Benfotiamine
- Drug: Placebo
|
Interventional
|
Phase 4 |
- University Medical Center Groningen
- Isala
- Wörwag Pharma GmbH & Co. KG
- Predictions Network
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in urinary excretion of: - Kidney injury molecule-1 (KIM-1) - Albumin
- Change in urinary excretion of: β2 microglobulin, macrophage inhibiting factor (MIF), monocyte chemo-attractant protein-1 (MCP-1), and other advanced glycation end-products (AGEs).
|
86 |
All |
40 Years to 75 Years (Adult, Older Adult) |
NCT00565318 |
BENFO-1
NL17390.075.07 |
Benfo |
December 2007 |
June 2009 |
June 2009 |
November 29, 2007 |
November 16, 2009 |
|
- Isala Klinieken Hospital
Zwolle, Netherlands
|
|
| 40 |
NCT01601236 |
Completed
Has Results |
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients |
|
- Drug: Repository Corticotropin Injection
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12
- Percent Change in eGFR at Visit 17
- Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death
- (and 7 more...)
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT01601236 |
QSC01-DN-01 |
|
May 2012 |
January 2016 |
March 2016 |
May 17, 2012 |
August 21, 2017 |
July 24, 2017 |
- Questcor Investigational Site
Roseville, California, United States - Questcor Investigational Site
Cooper City, Florida, United States - Questcor Investigational Site
Miami Springs, Florida, United States - (and 7 more...)
|
|
| 41 |
NCT01163591 |
Completed |
To Assess the Accuracy of the eZscan Study in the Screening for Diabetic Nephropathy |
|
|
Observational
|
|
- Chinese University of Hong Kong
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- The optimal eZscan unit to detect the presence of diabetic nephropathy as defined by eGFR and ACR using ROC analysis, sensitivity and specificity values.
- A prediction algorithm using age, sex, body mass index and eZcan score will be developed to predict eGFR as continuous and categorical variables using Cox regression analysis.
|
100 |
All |
21 Years to 75 Years (Adult, Older Adult) |
NCT01163591 |
CRE-2008.470-T |
|
January 2009 |
October 2009 |
October 2009 |
July 16, 2010 |
October 12, 2015 |
|
- Diabetes Mellitus and Endocrine Centre, Prince of Wales Hospital
Shatin, Hong Kong, China
|
|
| 42 |
NCT01109212 |
Completed |
The Effects of Bindarit in Diabetic Nephropathy |
|
- Drug: Bindarit
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Aziende Chimiche Riunite Angelini Francesco S.p.A
- Mario Negri Institute for Pharmacological Research
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Urinary Albumin Excretion (µg/min) levels in the overnight urine specimen.
- Urinary Monocyte Chemoattractant protein (MCP-1/CCL2)(pg/ml) levels in the overnight urine specimen.
- Serum lipids
- (and 2 more...)
|
100 |
All |
30 Years to 70 Years (Adult, Older Adult) |
NCT01109212 |
004SC06084
2006-006191-38 |
|
March 2007 |
November 2008 |
December 2008 |
April 23, 2010 |
March 30, 2016 |
|
- The Mario Negri Institute for Pharmacological Research- Clinical Research Center for Rare Diseases
Ranica, Bergamo, Italy - Azienda Ospedaliera di Treviglio-Caravaggio - Unità Operativa Malattie Metaboliche e Diabetologia
Treviglio, Bergamo, Italy - Azienda Ospedaliera OO.RR. Bergamo - Unità Operativa Diabetologia
Bergamo, Italy - (and 3 more...)
|
|
| 43 |
NCT01252056 |
Completed |
A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy |
|
- Drug: Probucol
- Drug: Probucol and Cilostazol
|
Interventional
|
Phase 4 |
- Otsuka Beijing Research Institute
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- nephropathy development
- IMT
- Atherosclerosis related biomarkers
- (and 2 more...)
|
353 |
All |
40 Years to 75 Years (Adult, Older Adult) |
NCT01252056 |
260-09-805-01 |
|
March 2010 |
December 2012 |
December 2012 |
December 2, 2010 |
May 8, 2013 |
|
- Beijing Universuty First Hospital
Beijng, Beijing, China
|
|
| 44 |
NCT00774904 |
Completed |
Adiponectin and Insulin Resistance in Diabetic Nephropathy |
|
|
Interventional
|
Not Applicable |
- Health Science Center of Xi’an Jiaotong University
- Shanghai Jiao Tong University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- GFR, HbA1c and the adiponectin concentration
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT00774904 |
ADPN |
|
April 2007 |
October 2007 |
November 2007 |
October 17, 2008 |
October 20, 2008 |
|
- Shanghai No.3 people's hospital
Shanghai, China
|
|
| 45 |
NCT02327754 |
Completed |
Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout |
|
- Drug: Topiroxostat BID, (Oral daily dosing for 28 weeks)
- Drug: Placebo BID, (Oral daily dosing for 28 weeks)
|
Interventional
|
Phase 2 |
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Fuji Yakuhin Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in urine albumin creatinine ratio
- sUA, eGFR, L-FABP, HbA1c, SBP, DBP, TC
|
60 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT02327754 |
FY1004 |
UPWARD |
|
December 2016 |
December 2016 |
December 30, 2014 |
April 12, 2017 |
|
- Sanwa Kagaku Kenkyusho Co., Ltd.
Nagoya, Aichi, Japan
|
|
| 46 |
NCT00340678 |
Completed
Has Results |
Renoprotection in Early Diabetic Nephropathy in Pima Indians |
|
- Drug: Losartan
- Drug: Placebo
|
Interventional
|
Phase 3 |
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants With Decline in GFR
- Glomerular Volume
|
170 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00340678 |
999995037
OH95-DK-N037 |
|
August 1995 |
May 2012 |
March 2014 |
June 21, 2006 |
July 24, 2014 |
November 19, 2013 |
- NIDDK, Phoenix
Phoenix, Arizona, United States
|
|
| 47 |
NCT01968668 |
Completed |
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan) |
|
- Drug: BAY94-8862
- Drug: Placebo
- Drug: BAY 94-8862
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change of urinary albumin-to creatinine ratio
- Change in serum potassium concentration
|
96 |
All |
18 Years and older (Adult, Older Adult) |
NCT01968668 |
16816 |
|
October 2013 |
October 2014 |
November 2014 |
October 24, 2013 |
January 9, 2015 |
|
- Nagoya, Aichi, Japan
- Nagoya, Aichi, Japan
- Saijo, Ehime, Japan
- (and 13 more...)
|
|
| 48 |
NCT00353600 |
Completed |
Delaying the Progression of Diabetic Nephropathy in Pima Indians |
|
|
Observational
|
|
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
25 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00353600 |
999994034
OH94-DK-N034 |
|
August 19, 1994 |
|
August 16, 2011 |
July 18, 2006 |
July 2, 2017 |
|
- NIDDK, Phoenix
Phoenix, Arizona, United States
|
|
| 49 |
NCT02676401 |
Completed |
An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy |
|
- Drug: MT-3995 Low
- Drug: MT-3995 Middle
- Drug: MT-3995 High
|
Interventional
|
Phase 2 |
- Mitsubishi Tanabe Pharma Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse events
- Change from baseline in Urine Albumin to Creatinine Ratio (UACR)
|
241 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT02676401 |
MT-3995-J06 |
|
February 2016 |
August 2017 |
|
February 8, 2016 |
September 18, 2017 |
|
- Touei Hospital
Hokkaido, Japan
|
|
| 50 |
NCT03284996 |
Not yet recruiting |
Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus. |
|
- Device: Doppler ultrasonography
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Early detection of diabetic nephropathy in patients with type 2 diabetes mellitus by measuring changes in renal resistive index using Doppler ultrasonography
|
80 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT03284996 |
DUDN |
|
October 1, 2017 |
April 30, 2019 |
September 1, 2019 |
September 15, 2017 |
September 15, 2017 |
|
|
|
| 51 |
NCT00664027 |
Completed |
Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy |
|
- Drug: RTA 402 (Bardoxolone Methyl)
|
Interventional
|
Phase 2 |
- Reata Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the effects of RTA 402 administered orally at three dose strengths on the glomerular filtration rate (as estimated by the MDRD formula) in patients with diabetic nephropathy (stratum 1).
- To determine the effects of RTA 402 on glomerular filtration rate (as estimated by the MDRD formula) when administered for 28 days at dose of 25 mg followed by a dose of 75 mg for another 28 days in patients with diabetic nephropathy (stratum 2).
- To evaluate the safety and tolerability of oral RTA 402 administered orally at three dose strengths in patients with diabetic nephropathy.
- (and 4 more...)
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT00664027 |
RTA 402-C-0801 |
|
April 2008 |
May 2009 |
|
April 22, 2008 |
December 3, 2012 |
|
- West Houston Clinical Research Services
Houston, Texas, United States - Renal Associates, PA
San Antonio, Texas, United States - DGD Research
San Antonio, Texas, United States
|
|
| 52 |
NCT03165240 |
Recruiting |
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 4 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated |
|
- Drug: BI 690517
- Drug: Eplerenone
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of patients with drug related Adverse Events (AEs)
- Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in morning void urine
- Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in daytime (10-hour) urine
|
105 |
All |
18 Years and older (Adult, Older Adult) |
NCT03165240 |
1378-0008
2017-000563-32 |
|
October 5, 2017 |
December 30, 2019 |
December 30, 2019 |
May 24, 2017 |
February 5, 2019 |
|
- Steno Diabetes Center Copenhagen
Gentofte, Denmark - Kolding Sygehus
Kolding, Denmark - Bispebjerg Hospital
København NV, Denmark - (and 27 more...)
|
|
| 53 |
NCT00136188 |
Completed |
Nitric Oxide (NO) Activity and Diabetic Nephropathy |
|
|
Interventional
|
Phase 2
Phase 3 |
- University of Erlangen-Nürnberg Medical School
|
Other |
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in renal endothelial function
|
100 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00136188 |
SFB 423 TP B5 |
|
August 2009 |
December 2011 |
December 2011 |
August 26, 2005 |
June 19, 2012 |
|
- CRC, Medizinische Klnik 4 - Nephrology and Hypertension, Uni Erlangen-Nürnberg
Erlangen, Germany
|
|
| 54 |
NCT00498537 |
Completed |
Spironolactone for Reducing Proteinuria in Diabetic Nephropathy |
|
|
Interventional
|
Not Applicable |
- US Department of Veterans Affairs
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- reduction in proteinuria
- Changes in GFR and incidence of hyperkalemia
|
30 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT00498537 |
0024 |
|
January 2003 |
December 2005 |
June 2006 |
July 10, 2007 |
October 17, 2008 |
|
- VA Medical Center, Dayton
Dayton, Ohio, United States
|
|
| 55 |
NCT00363987 |
Completed |
Controlled Study to Evaluate Efficacy and Safety of α-KA Tab With Low Protein Diet (LPD) in Delaying the Progress of Type 2 Diabetic Nephropathy (DN) |
|
- Drug: Ketosteril®
- Other: diabetic diet
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- changes in urine protein and GFR
- BMI(body mass index)
- Blood albumin and prealbumin
- (and 2 more...)
|
179 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00363987 |
BFP503 |
|
May 2006 |
December 2008 |
June 2009 |
August 15, 2006 |
September 2, 2010 |
|
- Shanghai Huashan Hospital
Shanghai, China
|
|
| 56 |
NCT01300273 |
Unknown † |
Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy |
- Type 2 Diabetic Nephropathy
|
- Dietary Supplement: Compound α-Ketoacid Tablet
|
Interventional
|
Phase 4 |
- Shanghai Jiao Tong University School of Medicine
- Huashan Hospital
- Shanghai East Hospital
- Shanghai 6th People's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- monitor podocyte loss by detecting nephrin, podocin, and synaptopodin mRNA in urine particulates with quantitative reverse transcriptase-PCR.
|
60 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01300273 |
KETO-011-IP4 |
|
February 2011 |
May 2012 |
July 2012 |
February 21, 2011 |
September 8, 2011 |
|
- Department of Nephrology,Shanghai Jiaotong University Affiliated First People's Hospital
Shanghai, Shanghai, China
|
|
| 57 |
NCT00153088 |
Completed |
INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy |
|
- Drug: Telmisartan capsule 40 mg
- Drug: Placebo
- Drug: Telmisartan capsule 80 mg
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Non-transition to overt nephropathy
- Change in renal parameters Composite endpoint
|
527 |
All |
30 Years to 74 Years (Adult, Older Adult) |
NCT00153088 |
502.413 |
|
January 2003 |
November 2005 |
November 2005 |
September 12, 2005 |
November 1, 2013 |
|
- Boehringer Ingelheim Investigational Site
Adachi-ku, Tokyo, Japan - Boehringer Ingelheim Investigational Site
Amagasaki, Hyogo, Japan - Boehringer Ingelheim Investigational Site
Arakawa-ku, Tokyo, Japan - (and 157 more...)
|
|
| 58 |
NCT02689778 |
Active, not recruiting |
Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy |
- Diabetic Nephropathy
- Albuminuria
|
- Drug: Pirfenidone
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Grupo Medifarma, S. A. de C. V.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Effect of oral pirfenidone (1800 mg) in albuminuria
- Effect of oral pirfenidone (1800 mg) in glomerular filtration rate
- Number of patients with treatment related adverse events
|
62 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02689778 |
1497 |
|
March 2016 |
March 2019 |
December 2019 |
February 24, 2016 |
May 7, 2018 |
|
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ)
Mexico City, Mexico
|
|
| 59 |
NCT02384902 |
Completed |
Effect of Low GI/ Glycemic Load (GL) Diet in Diabetic Nephropathy Patients |
- Diabetic Nephropathy
- Medication Compliance
|
- Other: low GI
- Other: conventional diet
|
Interventional
|
Not Applicable |
- Isfahan University of Medical Sciences
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Serum creatinine (and blood urea nitrogen (BUN) (mg/dL) were measured by colorimetric method and enzymatic colorimetric method using commercial assay kit.
- Serum levels of high sensitive C- reactive protein (hs-CRP) (mg/L) were quantified by using an ultrasensitive latex-enhanced immunoturbidimetric assay (Randox Laboratory Ltd., Belfast, United Kingdom).
|
90 |
All |
30 Years to 75 Years (Adult, Older Adult) |
NCT02384902 |
low GI nephropathy |
|
May 2014 |
July 2014 |
July 2014 |
March 10, 2015 |
March 10, 2015 |
|
- Leila Azadbakht
Isfahan, Iran, Islamic Republic of
|
|
| 60 |
NCT02986984 |
Recruiting |
Transformative Research in Diabetic Nephropathy |
- Diabetic Nephropathies
- Diabetic Glomerulosclerosis
|
- Other: There is no intervention
|
Observational
|
|
- University of Pennsylvania
- Columbia University
- MOUNT SINAI HOSPITAL
- (and 17 more...)
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rapid progression of kidney function loss
- Serious Adverse Events
|
300 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT02986984 |
824503 |
TRIDENT |
December 2016 |
November 2019 |
July 2020 |
December 8, 2016 |
November 14, 2018 |
|
- Stanford University
Palo Alto, California, United States - Yale University
New Haven, Connecticut, United States - University of Miami
Miami, Florida, United States - (and 13 more...)
|
|
| 61 |
NCT01094769 |
Unknown † |
Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease |
|
- Drug: Moxonidine
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Baker IDI Heart and Diabetes Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Urine albumin/creatinine ratio (UACR)
- muscle sympathetic nerve activity (MSNA)
|
48 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01094769 |
2010/10
58667 |
|
April 2011 |
January 2015 |
April 2015 |
March 29, 2010 |
December 18, 2013 |
|
- Alfred & Baker Medical Unit
Melbourne, Victoria, Australia
|
|
| 62 |
NCT00663949 |
Completed |
Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy |
|
- Drug: Captopril
- Drug: Captopril + Pentoxifylline
|
Interventional
|
Phase 2
Phase 3 |
- Shiraz University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- decreasing urinary protein
|
70 |
All |
30 Years to 70 Years (Adult, Older Adult) |
NCT00663949 |
3079 |
|
February 2006 |
December 2007 |
January 2008 |
April 22, 2008 |
April 22, 2008 |
|
- Shiraz University of Medical Sciences ,Nemazee and Faghihi Hospital
Shiraz, Fars, Iran, Islamic Republic of
|
|
| 63 |
NCT01874431 |
Completed |
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy |
|
- Drug: Finerenone (BAY 94-8862)
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change of Urinary Albumin-to-Creatinine Ratio (UACR) at Visit 90
- Change From Baseline to Day 90 in Serum Potassium
- Change From Baseline to Day 90 in Renal Function
- (and 2 more...)
|
823 |
All |
18 Years and older (Adult, Older Adult) |
NCT01874431 |
16243
2012-004179-38 |
ARTS-DN |
June 2013 |
July 2014 |
August 2014 |
June 11, 2013 |
August 13, 2015 |
|
- Birmingham, Alabama, United States
- Chula Vista, California, United States
- Los Angeles, California, United States
- (and 165 more...)
|
|
| 64 |
NCT01493050 |
Completed |
The Effects of Sevelamer Carbonate on Diabetic Nephropathy |
|
- Drug: Sevelamer Carbonate
- Drug: calcium carbonate
|
Interventional
|
Phase 2 |
- Gary Striker
- Icahn School of Medicine at Mount Sinai
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- glucose metabolism
- markers of inflammation and oxidative stress
- serum lipid levels
- serum phosphate level
|
117 |
All |
18 Years and older (Adult, Older Adult) |
NCT01493050 |
GCO 11-0973 |
|
February 2012 |
December 2013 |
December 2013 |
December 15, 2011 |
April 9, 2014 |
|
- Beth Israel Medical Center
New York, New York, United States - Icahn School of Medicine at Mount Sinai
New York, New York, United States
|
|
| 65 |
NCT00240019 |
Completed |
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease. |
|
- Drug: Addition of furosemide 20 mg oral bid to baseline regimen
|
Interventional
|
Not Applicable |
- Stanford University
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The amount of protein in the urine after 8 weeks of treatment.
- The estimated glomerular filtration rate after 8 weeks of treatment.
|
30 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00240019 |
R01-063011
R01DK063011 |
|
December 2003 |
|
April 2006 |
October 17, 2005 |
October 17, 2006 |
|
- Kaiser Permanente of Northern California, Santa Clara and San Jose
Santa Clara, California, United States - Stanford University Medical Center
Stanford, California, United States
|
|
| 66 |
NCT00120328 |
Terminated |
To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- To determine the effect of each dose of avosentan on time to doubling of serum creatinine, end stage renal disease (ESRD) or death when administered on top of standard treatment in subjects with type 2 diabetes mellitus and diabetic nephropathy.
- To determine the effect of each dose of avosentan on: cardiovascular mortality
- non-cardiovascular mortality
- (and 5 more...)
|
2364 |
All |
21 Years to 80 Years (Adult, Older Adult) |
NCT00120328 |
SPP301CRD15
2005-000604-14 |
|
July 2005 |
|
February 2007 |
July 15, 2005 |
October 5, 2007 |
|
- Dr. Mark Warren
Greenville, North Carolina, United States
|
|
| 67 |
NCT02194790 |
Completed |
Effect of Integrated CKD Care Program in Early Diabetic Nephropathy in Primary Health Care Setting. |
- Chronic Kidney Disease
- Diabetic Nephropathy
|
- Behavioral: Community-based Integrated CKD Care
|
Interventional
|
Not Applicable |
- Bhumirajanagarindra Kidney Institute, Thailand
- Ministry of Health, Thailand
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- The difference of rate of estimated glomerular filtration(eGFR) decline
- Change from baseline in Random Urine Albumin to Creatinine Ratio
- Change from baseline in waist circumference
- (and 3 more...)
|
238 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02194790 |
CICC program |
|
December 2012 |
December 2013 |
December 2013 |
July 18, 2014 |
July 18, 2014 |
|
- Bhumirajanagarindra Kidney Institute
Bangkok, Thailand
|
|
| 68 |
NCT02164279 |
Completed |
Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children |
- Type 1 Diabetes Mellitus With Diabetic Nephropathy
|
- Other: Urinary sample collection
|
Interventional
|
Not Applicable |
- University Hospital, Toulouse
- Laboratory Inserm U858 Team 5 – RF-lab
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Identify predictive non-invasive urinary biomarkers
- Relation of urinary markers with patient characteristics
|
140 |
All |
6 Years to 30 Years (Child, Adult) |
NCT02164279 |
12 356 03
2012-A01097-36 |
peeDIAB2 |
June 2013 |
December 2015 |
December 2015 |
June 16, 2014 |
January 12, 2016 |
|
- Purpan Children Hospital
Toulouse, France - Rangueil Hospital
Toulouse, France
|
|
| 69 |
NCT01726816 |
Completed |
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy |
|
- Drug: Probucol 250mg/day
- Drug: Probucol 500mg/day
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Korea Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- A/C ratio
- Serum creatinine
- eGFR
- (and 3 more...)
|
126 |
All |
20 Years to 80 Years (Adult, Older Adult) |
NCT01726816 |
009-KOA-1201i |
|
October 2012 |
April 2014 |
September 2014 |
November 15, 2012 |
May 3, 2017 |
|
- The Catholic university of Korea, Bucheon St. Mary's Hospital
Bucheon, Korea, Republic of - Kyungpook National University
DaeGu, Korea, Republic of - Yeungnam University Medical Center
DaeGu, Korea, Republic of - (and 13 more...)
|
|
| 70 |
NCT03445247 |
Recruiting |
Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy |
- Diabetic Nephropathy Type 2
|
- Other: Extracorporeal low-intensity shockwave
|
Interventional
|
Not Applicable |
- Chang Gung Memorial Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- changes of estimated glomerular filtration rate
- changes of proteinuria
- changes of systolic and diastolic blood pressure
|
60 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03445247 |
104-7771A |
|
July 1, 2017 |
June 30, 2019 |
June 30, 2020 |
February 26, 2018 |
February 26, 2018 |
|
- Kaohsiung Chang-Gung Memorial Hospital
Kaohsiung, Please Select, Taiwan
|
|
| 71 |
NCT01673204 |
Unknown † |
Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy |
|
- Drug: Calcitriol
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Seoul National University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Screening
|
- Changes in renal function with proteinuria
- changes in sTNFR and TNF-related proteins
|
276 |
All |
19 Years to 80 Years (Adult, Older Adult) |
NCT01673204 |
SNUH-TNFR |
|
October 2012 |
April 2014 |
|
August 27, 2012 |
February 13, 2014 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of - Seoul National University Boramae Medical Center
Seoul, Korea, Republic of
|
|
| 72 |
NCT03690180 |
Completed |
Hypomagnesemia and Diabetic Nephropathy |
|
- Diagnostic Test: serum magnesium
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Retrospective
|
- Decrease in serum magnesium
|
100 |
All |
20 Years and older (Adult, Older Adult) |
NCT03690180 |
VCG5 |
|
January 1, 2018 |
January 30, 2018 |
February 28, 2018 |
October 1, 2018 |
October 1, 2018 |
|
- Faculty of medicine Fayoum univesity
Fayoum, Egypt
|
|
| 73 |
NCT00448526 |
Terminated |
Effect of Low Protein Diet in Preventing the Progression of Diabetic Nephropathy |
|
- Behavioral: low protein diet
|
Interventional
|
Not Applicable |
- Kanazawa Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- annual change of GFR
- annual change of Ccr
- annual change of 1/Cr
- (and 4 more...)
|
|
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT00448526 |
H8-H-077 |
LPD |
December 1997 |
|
August 2006 |
March 19, 2007 |
March 19, 2007 |
|
|
|
| 74 |
NCT01843387 |
Completed |
Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy |
- Diabetic Nephropathy
- Type 2 Diabetes
|
- Biological: Mesenchymal Precursor Cells (MPCs)
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary objective of the study is to assess the safety and tolerability of MPC therapy
- Exploratory assessment of the efficacy of MPC therapy
|
30 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT01843387 |
MSB-DN001 |
|
July 2013 |
September 2014 |
September 2015 |
April 30, 2013 |
October 14, 2016 |
|
- Monash Universtiy
Clayton, Australia - Melbourne Renal Research Group
Melbourne, Australia
|
|
| 75 |
NCT00419835 |
Completed |
Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus |
- Macroalbuminuric Diabetic Nephropathy
|
- Drug: enalapril
- Drug: losartan
|
Interventional
|
Phase 4 |
- University of Sao Paulo
- Fundação de Amparo à Pesquisa do Estado de São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- effect of treatment on proteinuria after 8 months of follow-up
- effect of treatment on urinary inflammatory biomarkers after 8 months of follow-up
- incidence of hyperkalemia
|
80 |
All |
30 Years and older (Adult, Older Adult) |
NCT00419835 |
ST01 |
|
May 2005 |
September 2007 |
September 2007 |
January 9, 2007 |
August 4, 2011 |
|
- Nephrology Department, Sao Paulo University Medical School
Sao Paulo, Brazil
|
|
| 76 |
NCT03681704 |
Not yet recruiting |
the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD |
- Diabetic Nephropathy Type 2
|
- Drug: HuangQi Decoction
- Drug: HuangQi Decoction placebo
|
Interventional
|
Early Phase 1 |
- Shanghai University of Traditional Chinese Medicine
- Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
144 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03681704 |
17401970500-a |
|
October 2018 |
September 2021 |
September 2021 |
September 24, 2018 |
September 24, 2018 |
|
- Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai, China
|
|
| 77 |
NCT03681249 |
Recruiting |
the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD |
- Diabetic Nephropathy Type 2
|
- Drug: ShenqiDihuang Decoction
- Drug: ShenqiDihuang Decoction placebo
|
Interventional
|
Early Phase 1 |
- Shanghai University of Traditional Chinese Medicine
- Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
144 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03681249 |
17401970500-b |
|
November 2, 2018 |
September 2021 |
September 2021 |
September 24, 2018 |
November 9, 2018 |
|
- Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai, China
|
|
| 78 |
NCT03535935 |
Recruiting |
Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease |
- Diabetic Nephropathies
- Diabetic Kidney Disease
|
- Drug: Astragalus Powder
- Other: Routine medical care (active comparator)
|
Interventional
|
Phase 2
Phase 3 |
- The University of Hong Kong
- School of Chinese Medicine, The University of Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in estimated GFR
- Change in spot urine albumin-to-creatinine ratio
- Change in glycated haemoglobin (HbA1c)
- (and 4 more...)
|
118 |
All |
35 Years to 80 Years (Adult, Older Adult) |
NCT03535935 |
RE-02 |
READY |
July 1, 2018 |
June 30, 2022 |
December 31, 2022 |
May 24, 2018 |
October 11, 2018 |
|
- Queen Mary Hospital
Hong Kong, Hong Kong - School of Chinese Medicine
Hong Kong, Hong Kong
|
|
| 79 |
NCT03212755 |
Not yet recruiting |
Serum Immunoglobulin (G) as a Marker of Diabetic Nephropathy |
|
- Diagnostic Test: serum immunoglobulin G level
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- The number of patients with high level of immunoglobulin in serum
|
75 |
All |
30 Years to 70 Years (Adult, Older Adult) |
NCT03212755 |
PRUD |
|
August 2017 |
June 2019 |
December 2019 |
July 11, 2017 |
July 11, 2017 |
|
|
|
| 80 |
NCT01521910 |
Completed |
Effect of Dietary Protein Restriction on Prognosis in Patients With Diabetic Nephropathy |
- Type 1 Diabetes Mellitus With Diabetic Nephropathy
|
- Dietary Supplement: low protein diet
- Dietary Supplement: normal protein diet
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cumulative incidence of ESRD requiring dialysis or transplantation, and death
- Rate of decline of GFR
|
82 |
All |
18 Years to 60 Years (Adult) |
NCT01521910 |
Low Protein Diet |
LPD |
April 1995 |
June 2000 |
June 2000 |
January 31, 2012 |
January 31, 2012 |
|
- Steno Diabetes Center
Gentofte, Denmark
|
|
| 81 |
NCT00421733 |
Completed
Has Results |
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors |
- Diabetic Nephropathy
- Chronic Kidney Disease
|
- Drug: Zemplar (paricalcitol ) capsules
- Drug: Zemplar (paricalcitol) capsules
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine Collections Comparing Placebo to the Combined Paricalcitol Treatment Groups (1 Mcg and 2 Mcg).
- Number of Participants Achieving a 15% or Greater Reduction From Baseline to Last On-treatment Urine Albumin to Creatinine Ratio (UACR) Levels.
- Change From Baseline to the Last On-treatment Measurement in Albumin Levels Determined From 24-hour Urine Collection.
- Change From Baseline to the Last On-treatment Observation in Intact Parathyroid Hormone (iPTH) Levels.
|
281 |
All |
20 Years and older (Adult, Older Adult) |
NCT00421733 |
M05-741
2006-001363-31 |
VITAL |
December 2006 |
June 2009 |
June 2009 |
January 12, 2007 |
January 20, 2012 |
September 14, 2010 |
- Site Reference ID/Investigator# 862
Phoenix, Arizona, United States - Site Reference ID/Investigator# 864
Fountain Valley, California, United States - Site Reference ID/Investigator# 7291
Yuba City, California, United States - (and 69 more...)
|
|
| 82 |
NCT03625648 |
Not yet recruiting |
Pentoxifylline in Diabetic Kidney Disease |
|
- Drug: Pentoxifylline
- Drug: Placebo
|
Interventional
|
Phase 4 |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to ESRD or death
- Quality of life
- Time until doubling of serum creatinine
- (and 5 more...)
|
2510 |
All |
18 Years and older (Adult, Older Adult) |
NCT03625648 |
2008 |
PTXRx |
June 3, 2019 |
January 3, 2028 |
July 8, 2030 |
August 10, 2018 |
January 23, 2019 |
|
- Edward Hines Jr. VA Hospital, Hines, IL
Hines, Illinois, United States
|
|
| 83 |
NCT00312780 |
Completed |
Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy |
- Albuminuria
- Diabetic Nephropathy
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction in albumin excretion relative to creatinine
- Safety and tolerability
- Pharmacokinetics and renal elimination
|
125 |
All |
18 Years and older (Adult, Older Adult) |
NCT00312780 |
XL784-201 |
|
March 2006 |
October 2007 |
December 2007 |
April 11, 2006 |
February 23, 2010 |
|
- Parkway Medical Center
Birmingham, Alabama, United States - Winston Technology, Inc.
Haleyville, Alabama, United States - Redpoint Research
Phoenix, Arizona, United States - (and 42 more...)
|
|
| 84 |
NCT02156843 |
Terminated |
Pyridorin in Diabetic Nephropathy |
- Diabetic Nephropathy
- Diabetic Kidney Disease
|
- Drug: Pyridorin
- Drug: Placebo
|
Interventional
|
Phase 3 |
- NephroGenex, Inc.
- Collaborative Study Group (CSG)
- Medpace, Inc.
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to composite endpoint of >=50% SCr increase from baseline or ESRD
- Time to the composite endpoint >=100% SCr increase or ESRD
|
328 |
All |
18 Years and older (Adult, Older Adult) |
NCT02156843 |
PYR-311
2014-001641-24
CSG-17
PYR-311 (PIONEER) |
PIONEER |
June 2014 |
December 2017 |
March 2018 |
June 5, 2014 |
March 9, 2016 |
|
- CSG Investigational Site (#157)
Birmingham, Alabama, United States - CSG Investigational Site (#130)
Phoenix, Arizona, United States - CSG Investigational Site (#150)
Phoenix, Arizona, United States - (and 134 more...)
|
|
| 85 |
NCT01588795 |
Completed |
Renal Denervation in Diabetic Nephropathy |
- Diabetic Nephropathy
- Persistent Proteinuria With Type II Diabetes
|
- Procedure: Percutaneous renal denervation and TMNS
- Drug: Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
|
Interventional
|
Phase 4 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- proteinuria/creatininuria ratio
- Number of patients with a decrease of the PU/CrU >50% ratio
- Evaluation of the slope of decay of the PU/CrU
- (and 9 more...)
|
25 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01588795 |
P110122 |
DERENEDIAB |
April 2012 |
January 2016 |
January 2016 |
May 1, 2012 |
June 1, 2016 |
|
- CIC Hopital europeen george pompidou
Paris, France
|
|
| 86 |
NCT01566006 |
Unknown † |
Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration |
- Diabetic Nephropathy
- Chronic Kidney Disease
|
- Drug: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
|
Interventional
|
Not Applicable |
- The Nazareth Hospital, Israel
- Western Galilee Hospital-Nahariya
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
80 |
All |
30 Years to 80 Years (Adult, Older Adult) |
NCT01566006 |
nazh8827ctil |
Myridian |
April 2012 |
June 2013 |
August 2013 |
March 29, 2012 |
March 29, 2012 |
|
- Nazareth hospital (EMMS)
Nazareth, Israel
|
|
| 87 |
NCT02501772 |
Unknown † |
The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy |
|
- Device: acupressure by ankle band
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- urinary spot albumin creatine excretion ratio (UACR) change
|
60 |
All |
20 Years to 80 Years (Adult, Older Adult) |
NCT02501772 |
14MMHIS139 |
|
September 2014 |
August 2015 |
September 2015 |
July 17, 2015 |
July 28, 2015 |
|
- Mackay Memerial Hospital
Taipei, Taiwan
|
|
| 88 |
NCT02251067 |
Completed |
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients |
|
- Drug: VPI-2690B low dose
- Drug: VPI-2690B medium dose
- Drug: Placebo to match VPI-2690B
- Drug: VPI-2690B high dose
|
Interventional
|
Phase 2 |
- Vascular Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in albuminuria
- Change from baseline in eGFR
|
165 |
All |
21 Years to 80 Years (Adult, Older Adult) |
NCT02251067 |
VPI-CLIN-201-AD |
|
September 2014 |
March 2017 |
March 2017 |
September 26, 2014 |
March 28, 2017 |
|
- Birmingham, Alabama, United States
- Little Rock, Arkansas, United States
- La Mesa, California, United States
- (and 31 more...)
|
|
| 89 |
NCT00130208 |
Completed
Has Results |
Effect of Sulodexide in Early Diabetic Nephropathy |
|
- Drug: Sulodexide
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Keryx Biopharmaceuticals
- Collaborative Study Group (CSG)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria
- Number of Subjects With Greater Than 50% Reduction in Microalbuminuria
- Change in Serum Albumin From Baseline to End of 26 Weeks
|
1056 |
All |
18 Years and older (Adult, Older Adult) |
NCT00130208 |
KRX-101-301 |
|
August 2005 |
January 2008 |
February 2008 |
August 15, 2005 |
March 23, 2018 |
March 23, 2018 |
- The Collaborative Study Group, Clinical Coordinating Center for U.S. and Canadian Clinics, Rush University Medical Center
Chicago, Illinois, United States - The Collaborative Study Group, Clinical Coordinating Center for the Pacific Region, Monash Medical Center
Melbourne, Victoria, Australia - The Collaborative Study Group, Clinical Coordinating Center for European Clinics, University of Groningen
Groningen, Netherlands
|
|
| 90 |
NCT03820635 |
Not yet recruiting
New |
Markers of Vascular Calcification in Diabetic Nephropathy in Patients With Diabetic Nephropathy |
- Diabetic Nephropathies
- Vascular Calcification
|
- Diagnostic Test: Osteopontin (OPN)
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- correlation coefficient between serum level of osteoponton and the rate of different aspects of vascular affection as discussed previously
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03820635 |
MVasCDN |
|
March 1, 2019 |
July 1, 2020 |
September 1, 2020 |
January 29, 2019 |
January 29, 2019 |
|
- Assiut University
Asyūţ, Egypt
|
|
| 91 |
NCT01923597 |
Completed |
Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy. |
- Diabetic Nephropathy
- Hypertension
|
|
Interventional
|
Phase 2 |
- University of Campinas, Brazil
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Effect of green tea (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.
- Effect of green tea (epigallocatechin gallate) on oxidative stress in patients with diabetic nephropathy.
- Effect of green tea (epigallocatechin gallate) on blood glucose control in patients with diabetic nephropathy.
- (and 3 more...)
|
50 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT01923597 |
Fapesp-2013 |
|
November 2013 |
March 2015 |
March 2015 |
August 15, 2013 |
August 4, 2016 |
|
- Unicamp
Campinas, São Paulo, Brazil
|
|
| 92 |
NCT00518362 |
Completed |
To Compare the Efficacy and Safety of Tripterygium (TW) Versus Valsartan in the Diabetic Nephropathy (DN) |
|
|
Interventional
|
Not Applicable |
- Nanjing University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of diabetic nephropathy
- To investigate the safety and tolerability of TW vs ARB. To access whether TW can delay the progression to ESRD or creatinine-doubling in diabetic nephropathy with heavy proteinuria.
|
67 |
All |
35 Years to 65 Years (Adult, Older Adult) |
NCT00518362 |
NJCT-0701 |
|
July 2007 |
September 2009 |
March 2010 |
August 20, 2007 |
May 27, 2010 |
|
- Research Institute of Nephrology
Nanjing, Jiangsu, China
|
|
| 93 |
NCT00067678 |
Completed |
Soy Protein in Early Diabetic Nephropathy |
- Diabetic Nephropathy
- Diabetes Mellitus
|
|
Interventional
|
Phase 1
Phase 2 |
- National Center for Complementary and Integrative Health (NCCIH)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 40 Years (Adult) |
NCT00067678 |
R21AT000323-01 |
|
July 2001 |
|
June 2003 |
August 27, 2003 |
August 18, 2006 |
|
- University of Kentucky
Lexington, Kentucky, United States
|
|
| 94 |
NCT03622762 |
Recruiting |
Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy |
- Diabetic Nephropathy Type 2
|
- Drug: green tea extract
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Centro Universitario de Ciencias de la Salud, Mexico
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Soluble RAGE concentration
- Glomerular filtration rate
- Albumin/creatinine ratio
- (and 5 more...)
|
30 |
All |
40 Years to 65 Years (Adult, Older Adult) |
NCT03622762 |
CUCS-INTEC-MV-ERVE-06 |
|
July 15, 2018 |
December 15, 2018 |
June 20, 2019 |
August 9, 2018 |
August 21, 2018 |
|
- Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara
Guadalajara, Jalisco, Mexico
|
|
| 95 |
NCT01967901 |
Completed |
Impact of Multidisciplinary Self-care Management of Diabetic Nephropathy on Quality of Life, Self-care Behavior, Glycemic Control, and Renal Function. |
|
- Behavioral: Self-care management program
|
Interventional
|
Not Applicable |
- University of Applied Sciences of Western Switzerland
- University of Lausanne
- University of Lausanne Hospitals
- Leenaards Fondation, Switzerland
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Quality of life
- Self-care
- The adherence to anti-hypertensive medication
- (and 2 more...)
|
36 |
All |
18 Years to 95 Years (Adult, Older Adult) |
NCT01967901 |
37319/S-RAD13-07 |
|
March 2014 |
February 2016 |
February 2016 |
October 23, 2013 |
May 18, 2016 |
|
- University of Lausanne Hospitals
Lausanne, Vaud, Switzerland
|
|
| 96 |
NCT03165227 |
Recruiting |
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses) |
|
- Drug: BI 685509
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of patients with drug related Adverse Events (AEs)
- Change from baseline in log transformed Urine albumin creatinine ratio (UACR) measured in morning void urine
- Change from baseline in log transformed Urine albumin creatinine ratio (UACR) measured in 10-hour urine
|
75 |
All |
18 Years and older (Adult, Older Adult) |
NCT03165227 |
1366-0004
2014-004541-27 |
|
October 17, 2017 |
November 15, 2019 |
November 15, 2019 |
May 24, 2017 |
February 12, 2019 |
|
- California Institute of Renal Research
La Mesa, California, United States - Office of Dr. Richard S. Cherlin
Los Gatos, California, United States - Creekside Endocrine Associates, PC
Denver, Colorado, United States - (and 31 more...)
|
|
| 97 |
NCT00914524 |
Completed |
Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy |
- Chronic Glomerulonephritis
- Diabetic Nephropathy
|
- Drug: olmesartan medoxomil
|
Interventional
|
Phase 2 |
- Daiichi Sankyo Co., Ltd.
- Daiichi Sankyo, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The change in the urinary protein/creatinine ratio from baseline to the end of treatment.
- The change of creatinine clearance
|
49 |
All |
20 Years to 70 Years (Adult, Older Adult) |
NCT00914524 |
CS0866-C-J201 |
|
January 2005 |
April 2006 |
October 2006 |
June 5, 2009 |
September 29, 2010 |
|
|
|
| 98 |
NCT02040441 |
Completed |
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria |
- Diabetic Nephropathy
- Diabetic Retinopathy
|
- Drug: Spironolactone
- Drug: Placebo
- Drug: Standard care
|
Interventional
|
Phase 2
Phase 3 |
- Peter Rossing
- Mosaiques Diagnostics GmbH
- University Medical Center Groningen
- (and 16 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Albuminuria
- Cardiovascular disease and mortality
- Retinopathy
- (and 5 more...)
|
1777 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02040441 |
2012-000452-34 |
PRIORITY |
March 2014 |
November 2018 |
November 2018 |
January 20, 2014 |
December 21, 2018 |
|
- Universitair Ziekenhuis
Gent, Belgium - Institut Klinické a Experimentální Mediciny
Prague, Czechia - Universita Karlova v Praze
Prague, Czechia - (and 12 more...)
|
|
| 99 |
NCT01331317 |
Completed |
Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy |
- Cardiovascular Disease
- Diabetic Nephropathy
|
|
Interventional
|
Phase 4 |
- Peter Rossing
- Abbott
- Steno Diabetes Center
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in plasma NT-proBNP
- Change in Glomerular Filtration Rate (GFR)
- Change in Urinary Albumin Excretion Rate
|
48 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01331317 |
2009-011255-44 |
|
April 2010 |
April 2012 |
April 2012 |
April 8, 2011 |
April 13, 2012 |
|
- Steno Diabetes Center A/S
Gentofte, Denmark
|
|
| 100 |
NCT02065791 |
Completed |
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy |
- Diabetes Mellitus, Type 2
- Diabetic Nephropathy
|
- Drug: Canagliflozin
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
- The George Institute for Global Health, Australia
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time to the First Occurrence of an Event in the Primary Composite Endpoint
- Time to the First Occurrence of an Event in the Composite Endpoint of CV Death and Hospitalized Congestive Heart Failure
- Time to the First Occurrence of an Event in the Composite Endpoint of CV death, Non-fatal MI, and Non-fatal Stroke (that is, 3-Point Major Adverse Cardiac Event [MACE])
- (and 5 more...)
|
4402 |
All |
30 Years and older (Adult, Older Adult) |
NCT02065791 |
CR103517
2013-004494-28
28431754DNE3001 |
CREDENCE |
February 17, 2014 |
October 30, 2018 |
October 30, 2018 |
February 19, 2014 |
January 25, 2019 |
|
- Birmingham, Alabama, United States
- Montgomery, Alabama, United States
- Tempe, Arizona, United States
- (and 590 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: